Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Arthritis
Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Arthritis
Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis.
Arthritis, Rheumatoid
Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis.
Arthritis, Rheumatoid
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Arthritis, Rheumatoid
Dual binding mode of a novel series of DHODH inhibitors.
Arthritis, Rheumatoid
Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases.
Arthritis, Rheumatoid
Precision Medicine with Leflunomide: Consideration of DHODH Haplotype and Plasma Teriflunomide Concentration can Substantially Modify Outcomes in Patients with Rheumatoid Arthritis.
Arthritis, Rheumatoid
Preparation of human dihydroorotate dehydrogenase for interaction studies with lipid bilayers.
Arthritis, Rheumatoid
Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors.
Autoimmune Diseases
4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease.
Autoimmune Diseases
A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial.
Autoimmune Diseases
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Autoimmune Diseases
Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors.
Autoimmune Diseases
IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Autoimmune Diseases
Natural product piperine alleviates experimental allergic encephalomyelitis in mice by targeting dihydroorotate dehydrogenase.
Autoimmune Diseases
Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors.
Autoimmune Diseases
Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents.
Breast Neoplasms
Cis-eQTL-based trans-ethnic meta-analysis reveals novel genes associated with breast cancer risk.
Breast Neoplasms
Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Carcinogenesis
Energy Metabolism Rewiring Precedes UVB-Induced Primary Skin Tumor Formation.
Carcinogenesis
Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells.
Carcinoma
Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Carcinoma
Dihydroorotate dehydrogenase is required for N-(4-hydroxyphenyl)retinamide-induced reactive oxygen species production and apoptosis.
Carcinoma
Elevated DHODH expression promotes cell proliferation via stabilizing ?-catenin in esophageal squamous cell carcinoma.
Carcinoma
The Role of Dihydroorotate Dehydrogenase in Apoptosis Induction in Response to Inhibition of the Mitochondrial Respiratory Chain Complex III.
Chagas Disease
Computational study of the mechanism of half-reactions in class 1A dihydroorotate dehydrogenase from Trypanosoma cruzi.
Colorectal Neoplasms
PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis.
COVID-19
A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors.
COVID-19
A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial.
COVID-19
Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
Cysts
Expression of the dihydroorotate dehydrogenase gene, dhod, during spermatogenesis in Drosophila melanogaster.
dihydroorotate dehydrogenase (fumarate) deficiency
Elevated plasma dihydroorotate in Miller syndrome: Biochemical, diagnostic and clinical implications, and treatment with uridine.
Dysostoses
Miller (Genee-Wiedemann) syndrome represents a clinically and biochemically distinct subgroup of postaxial acrofacial dysostosis associated with partial deficiency of DHODH.
Dysostoses
Mitochondrial nucleic acid binding proteins associated with diseases.
Dysostoses
Targeted Next-Generation Sequencing in the Diagnosis of Facial Dysostoses.
Esophageal Squamous Cell Carcinoma
Elevated DHODH expression promotes cell proliferation via stabilizing ?-catenin in esophageal squamous cell carcinoma.
Foot-and-Mouth Disease
Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus.
Genetic Diseases, Inborn
Preparation of human dihydroorotate dehydrogenase for interaction studies with lipid bilayers.
Glioblastoma
Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
Glioblastoma
The transcription factors aryl hydrocarbon receptor and MYC cooperate in the regulation of cellular metabolism.
Glioma
Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
Hematologic Neoplasms
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase.
Hematologic Neoplasms
Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.
Herpes Simplex
Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication.
Hypersensitivity
Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl ] propenamide and related compounds.
Infections
In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model.
Influenza, Human
Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
Influenza, Human
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Leishmaniasis
Crystal structure of dihydroorotate dehydrogenase from Leishmania major.
Leishmaniasis
Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
Leishmaniasis, Cutaneous
Crystal structure of dihydroorotate dehydrogenase from Leishmania major.
Leukemia
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Leukemia, Myeloid
A combined Chemical, Computational and invitro approach identifies SBL 105 as novel DHODH inhibitor in Acute Myeloid Leukemia cells.
Leukemia, Myeloid, Acute
A combined Chemical, Computational and invitro approach identifies SBL 105 as novel DHODH inhibitor in Acute Myeloid Leukemia cells.
Leukemia, Myeloid, Acute
Development of ML390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes.
Leukemia, Myeloid, Acute
Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
Leukemia, Myeloid, Acute
Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Leukemia, Myeloid, Acute
The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia.
Lung Neoplasms
Identification of DHODH as a therapeutic target in small cell lung cancer.
Lymphocytic Choriomeningitis
Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity against Mammarenaviruses In Vitro.
Lymphoma
Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
Lymphoma
Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase.
Lymphoma
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase.
Malaria
A high-throughput fluorescence-based assay for Plasmodium dihydroorotate dehydrogenase inhibitor screening.
Malaria
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.
Malaria
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Malaria
Optimization of Potent Inhibitors of P. falciparum Dihydroorotate Dehydrogenase for the Treatment of Malaria.
Malaria
Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series.
Malaria
Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors.
Malaria
Structural basis for the function and inhibition of dihydroorotate dehydrogenase from Schistosoma mansoni.
Malaria
Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.
Malaria
Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.
Malaria
The X-ray structure of Plasmodium falciparum dihydroorotate dehydrogenase bound to a potent and selective N-phenylbenzamide inhibitor reveals novel binding-site interactions.
Mandibulofacial Dysostosis
Targeted Next-Generation Sequencing in the Diagnosis of Facial Dysostoses.
Measles
Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH).
Melanoma
Computational and experimental prediction of molecules involved in the anti-melanoma action of berberine.
Melanoma
DHODH modulates transcriptional elongation in the neural crest and melanoma.
Melanoma
Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase.
Melanoma
Inactivation/deficiency of DHODH induces cell cycle arrest and programed cell death in melanoma.
Melanoma
Synergistic inhibition of melanoma xenografts by Brequinar sodium and Doxorubicin.
Melanoma
The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells.
Metabolism, Inborn Errors
Choline-related-inherited metabolic diseases-A mini review.
Mouth Diseases
Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus.
Multiple Myeloma
Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells.
Multiple Sclerosis
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Multiple Sclerosis
Preparation of human dihydroorotate dehydrogenase for interaction studies with lipid bilayers.
Multiple Sclerosis, Relapsing-Remitting
Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis.
Myelodysplastic Syndromes
DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes.
Neoplasm Metastasis
PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis.
Neoplasms
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Neoplasms
Checkpoint kinase 1 inhibition sensitises transformed cells to dihydroorotate dehydrogenase inhibition.
Neoplasms
Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers.
Neoplasms
Design, Synthesis, and Characterization of Brequinar Conjugates as Probes to Study DHODH Inhibition.
Neoplasms
DHODH and cancer: promising prospects to be explored.
Neoplasms
DHODH inhibition modulates glucose metabolism and circulating GDF15, and improves metabolic balance.
Neoplasms
DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer.
Neoplasms
Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Neoplasms
Dihydroorotate dehydrogenase in oxidative phosphorylation and cancer.
Neoplasms
Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
Neoplasms
Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase.
Neoplasms
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Neoplasms
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Neoplasms
Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
Neoplasms
Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis.
Neoplasms
Metabolomics profiles delineate uridine deficiency contributes to mitochondria-mediated apoptosis induced by celastrol in human acute promyelocytic leukemia cells.
Neoplasms
Mitochondrial ubiquinol oxidation is necessary for tumour growth.
Neoplasms
Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
Neoplasms
Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Neoplasms
Quantitation of uridine and L-dihydroorotic acid in human plasma by LC-MS/MS using a surrogate matrix approach.
Neoplasms
Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells.
Neoplasms
Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors.
Neoplasms
Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Neoplasms
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase.
Neoplasms
SOX2-dependent expression of dihydroorotate dehydrogenase regulates oral squamous cell carcinoma cell proliferation.
Neoplasms
Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents.
Neoplasms
The pathway to pyrimidines: The essential focus on dihydroorotate dehydrogenase, the mitochondrial enzyme coupled to the respiratory chain.
Neoplasms
The Role of Dihydroorotate Dehydrogenase in Apoptosis Induction in Response to Inhibition of the Mitochondrial Respiratory Chain Complex III.
Neoplasms
The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia.
Neoplasms
Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma.
Neoplasms
Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.
Neoplasms
UVB-induced DHODH upregulation, which is driven by STAT3, is a promising target for chemoprevention and combination therapy of photocarcinogenesis.
Neuroblastoma
Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo.
Neuroblastoma
Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma.
Oral Ulcer
Non-healing tongue ulcer in a rheumatoid arthritis patient medicated with leflunomide. An adverse drug event?
Parasitic Diseases
Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.
Psoriasis
Evaluation of WO2013076170: the use of a dihydroorotate dehydrogenase inhibitor for the treatment of psoriasis.
Psoriasis
Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors.
Schistosomiasis
Structural basis for the design of selective inhibitors for Schistosoma mansoni dihydroorotate dehydrogenase.
Skin Neoplasms
UVB-induced DHODH upregulation, which is driven by STAT3, is a promising target for chemoprevention and combination therapy of photocarcinogenesis.
Small Cell Lung Carcinoma
Identification of DHODH as a therapeutic target in small cell lung cancer.
Vesicular Stomatitis
Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses.
Vesicular Stomatitis
Inhibition of pyrimidine synthesis reverses viral virulence factor-mediated block of mRNA nuclear export.
Virus Diseases
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1.3.98.1 dihydroorotate dehydrogenase (fumarate)
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
